Pages that link to "Q50612699"

The following pages link to Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols (Q50612699):

Displaying 24 items.

• Ganciclovir. A pharmacoeconomic review of its use as intravenous or oral maintenance therapy in the management of cytomegalovirus retinitis in patients with AIDS. (Q33576431) (← links)
• Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. (Q33584119) (← links)
• Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery (Q34078012) (← links)
• Cost-effectiveness of voluntary HIV screening in Russia (Q34308731) (← links)
• AIDS policy modeling for the 21st century: an overview of key issues (Q34344685) (← links)
• Using simulation for AIDS policy modeling: benefits for HIV/AIDS prevention policy makers in Vienna, Austria (Q34626793) (← links)
• Everyday and exotic foodborne parasites (Q36170163) (← links)
• Cost-effectiveness of HIV screening in patients older than 55 years of age. (Q36191220) (← links)
• Cost-effectiveness of HIV counseling and testing in US prisons (Q36273908) (← links)
• Economic models of antiretroviral therapy: searching for the optimal strategy (Q36520576) (← links)
• HIV Risk Behavior among Outpatients at a State Psychiatric Hospital: Prevalence and Risk Modeling (Q37269794) (← links)
• The cost and incidence of prescribing errors among privately insured HIV patients (Q37656198) (← links)
• Cost-effective management of benign positional vertigo using canalith repositioning (Q38500057) (← links)
• Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers (Q40485588) (← links)
• Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women (Q42598223) (← links)
• Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease (Q45081834) (← links)
• Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment? (Q46314766) (← links)
• A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US. (Q46702945) (← links)
• Updates of Cost of Illness and Quality of Life Estimates for Use in Economic Evaluations of HIV Prevention Programs (Q50176584) (← links)
• Beyond the biomedical and behavioural: towards an integrated approach to HIV prevention in the southern African mining industry (Q52175906) (← links)
• HIV transmission and the cost-effectiveness of methadone maintenance (Q52278638) (← links)
• Cost and Financing of Care for Persons With HIV Disease: An Overview. (Q55690003) (← links)
• Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection (Q57181637) (← links)
• Cost-Utility Analysis of Prophylactic Treatment With Oral Ganciclovir for Cytomegalovirus Retinitis (Q73896050) (← links)